Evaluation of valaciclovir dosage reduction in continuous ambulatory peritoneal dialysis patients

Nephron

Volumn 91, Issue 1, 2002, Pages 164-166

  Stathoulopoulou, F ^a,d   Dhillon, S ^a   Thodis, H ^b   Stathakis, C ^c   Vargemezis, V ^b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c LAIKO GENERAL HOSPITAL   (Greece)

^d NONE   (Greece)

Author keywords

CAPD; Valaciclovir dosage; Valaciclovir, neurotoxicity; Valaciclovir, relative pharmacokinetics

Indexed keywords

ACICLOVIR; VALACICLOVIR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; HERPES ZOSTER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; MALE; NEUROTOXICITY; PRIORITY JOURNAL; TREATMENT OUTCOME;

ACYCLOVIR; AGED; ANTIVIRAL AGENTS; BIOLOGICAL AVAILABILITY; FEMALE; HERPES ZOSTER; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; VALINE;

EID: 0036095122     PISSN: 00282766     EISSN: None     Source Type: Journal    
DOI: 10.1159/000057621     Document Type: Article

References (6)

1. Acyclovir: A decade later
2. Valaciclovir
3. Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans
4. Monitoring the safety of antivirals. The example of the acyclovir experience
5. Rapid determination of valaciclovir and acyclovir in human biological fluids by high-performance liquid chromatography using isocratic elution
6. Determination of peritoneal transport characteristics with 24-hour dialysate collections: Dialysis adequacy and transport test